Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of GED-0301 in active ileocolonic Crohn's disease
2011-002640-27Phase 2Completed
- Sponsor
- Giuliani
- Start
- Feb 2012
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing GED-0301 with Placebo (2 arms). Primary endpoints: Clinical remission at day 15 maintained through week 4 and Safety of 14-day oral GED-0301. Started Feb 2012; status: completed.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-002640-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002640-27.